ID

35332

Descrizione

Study ID: 101222 Clinical Study ID: 101222 Study Title: Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT) Trade Name:Zilbrix/Hib Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Keywords

versioni (2)
  1. 27/02/19 27/02/19 -
  2. 28/02/19 28/02/19 -
Titolare del copyright

GSK group of companies

Caricato su

28 febbraio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Immunogenicity of TPw-HBV/Hib Kft. Vaccine in healthy infants - 101222

Inglese

VISIT 1 (Day 0 Birth)

1 moduli  
  1. StudyEvent: ODM
    1. VISIT 1 (Day 0 Birth)
ELIMINATION CRITERIA DURING THE STUDY
Descrizione

ELIMINATION CRITERIA DURING THE STUDY

Subject Number
Descrizione

Subject Number

Tipo di dati

text

Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the combined DTPw-HepB vaccine or DTPw-HepB/Hib vaccine, with the exception of oral poliovirus vaccine (OPV).
Descrizione

The following criteria should be checked at Visit 2. If any become applicable during the study, it will not require withdrawal of the subject from the study but does determine a subject’s evaluability in the according-to-protocol analysis (ATP) analysis.

Tipo di dati

boolean

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Descrizione

Elimination Criteria Unplanned Concomitant Medication

Tipo di dati

boolean

Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Descrizione

Elimination Criteria Immunodepressants

Tipo di dati

boolean

Hepatitis B vaccine received after the first 72 hours of life.
Descrizione

Elimination Criteria Prior Hepatitis B Vaccine

Tipo di dati

boolean

Bacille Calmette-Guérin (BCG) vaccine given after the first 2 weeks of life.
Descrizione

Elimination Criteria Prior BCG Vaccine

Tipo di dati

boolean

Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae or hepatitis B (except if indicated in the group allocation).
Descrizione

Elimination Criteria Previous Vaccination

Tipo di dati

boolean

History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B or Hib diseases.
Descrizione

Elimination Criteria History of Diphteria

Tipo di dati

boolean

Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
Descrizione

Elimination Criteria Immunodeficient condition

Tipo di dati

boolean

History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Descrizione

Elimination Criteria Allergies

Tipo di dati

boolean

Administration of immunoglobulins and/ or any blood products during the study period.
Descrizione

Elimination Criteria Immuniglobulins

Tipo di dati

boolean

Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period.
Descrizione

The following criteria should be checked at Visits 3, 4 and 5. If any become applicable during the study, it will not require withdrawal of the subject from the study but does determine a subject’s evaluability in ATP analysis.

Tipo di dati

boolean

Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Descrizione

Elimination Criteria Immunosuppressants

Tipo di dati

boolean

Planned administration/ administration of a vaccine not foreseen by the study protocol during the period from 30 days before each dose of vaccine and ending 30 after the last dose of vaccine, with the exception of OPV.
Descrizione

Elimination Criteria Planned Concomitant Vaccination

Tipo di dati

boolean

Administration of immunoglobulins and/or any blood products during the study period.
Descrizione

Elimination Criteria Immunoglobulins

Tipo di dati

boolean

Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing required at study entry).
Descrizione

Elimination Criteria History of Immunodeficiency

Tipo di dati

boolean

CONTRAINDICATIONS TO SUBSEQUENT VACCINATION
Descrizione

CONTRAINDICATIONS TO SUBSEQUENT VACCINATION

Anaphylactic reaction following the administration of vaccines.
Descrizione

The following adverse events (AEs) constitute absolute contraindications to further administration of the study vaccines; if any of these AEs occur during the study, the subject must not receive additional doses of vaccine but may continue other study procedures at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE :

Tipo di dati

boolean

Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines.
Descrizione

hypersensitivity to vaccine

Tipo di dati

boolean

Encephalopathy (not due to another identifiable cause).
Descrizione

This is defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination, and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours. Even though causation by DTP vaccine cannot be established, no subsequent doses of pertussis vaccine should be given. In these circumstances the vaccination course should be continued with DT and HB vaccines.

Tipo di dati

boolean

Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature < 37.5 °C or rectal temperature < 38 °C.)
Descrizione

The following AEs constitute contraindications to administration of the study vaccines at that point in time; if any one of these AEs occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.

Tipo di dati

boolean

Axillary or oral temperature >= 37.5 °C or Rectal temperature >= 38 °C at the time of vaccination.
Descrizione

Temperature

Tipo di dati

boolean

PRECAUTIONS
Descrizione

PRECAUTIONS

Fever = 40.0 °C (preferable axillary temperature or oral temperature) within 48 hours of vaccination, not due to another identifiable cause.
Descrizione

If any of the following events occur in temporal relation to receipt of study vaccines, the decision to give subsequent doses of vaccine containing the pertussis component should be carefully considered.

Tipo di dati

boolean

Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
Descrizione

Collapse or Shock

Tipo di dati

boolean

Persistent crying lasting >= 3 hours, occurring within 48 hours of vaccination.
Descrizione

Crying

Tipo di dati

boolean

Convulsions with or without fever, occurring within 3 days of vaccination. There may be circumstances, such as a high incidence of pertussis, when the potential benefits outweigh possible risks.
Descrizione

A history of febrile convulsions, a family history of convulsions, a family history of Sudden Infant Death Syndrome (SIDS) and a family history of an adverse event following TritanrixTM-HepB vaccination do not constitute contraindications.

Tipo di dati

boolean

Reminder
Descrizione

Reminder

Tipo di dati

text

INFORMED CONSENT
Descrizione

INFORMED CONSENT

I certify that Informed Consent has been obtained prior to any study procedure.
Descrizione

Informed Consent

Tipo di dati

boolean

Informed Consent Date:
Descrizione

Informed Consent Date

Tipo di dati

date

DEMOGRAPHICS
Descrizione

DEMOGRAPHICS

Center number:
Descrizione

Center number

Tipo di dati

integer

Date of birth:
Descrizione

Date of birth

Tipo di dati

date

Gender:
Descrizione

Gender

Tipo di dati

text

Race:
Descrizione

Race

Tipo di dati

text

ELIGIBILITY CHECK
Descrizione

ELIGIBILITY CHECK

Did the subject meet all the entry criteria?
Descrizione

If No, tick all boxes corresponding to violations of any inclusion/exclusion criteria; Do not enter the subject into the study if he/she failed any inclusion or exclusion criteria below.

Tipo di dati

boolean

INCLUSION CRITERIA
Descrizione

INCLUSION CRITERIA

Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
Descrizione

Tick the boxes corresponding to any of the inclusion criteria the subject failed

Tipo di dati

boolean

Born to a mother known to be seronegative for HBsAg (documented laboratory result of HBsAg assay from a maternal blood sample is available).
Descrizione

Tick the boxes corresponding to any of the inclusion criteria the subject failed

Tipo di dati

boolean

Written informed consent obtained from the parent or guardian of the subject.
Descrizione

Tick the boxes corresponding to any of the inclusion criteria the subject failed

Tipo di dati

boolean

Free of obvious health problems as established by medical history and clinical examination before entering into the study.
Descrizione

Tick the boxes corresponding to any of the inclusion criteria the subject failed

Tipo di dati

boolean

Born after a normal gestation period (between 36 and 42 weeks).
Descrizione

Tick the boxes corresponding to any of the inclusion criteria the subject failed

Tipo di dati

boolean

A male or female less than or equal to 3 days (72 hours) of age at the time of the birth dose of Hepatitis B vaccination, if indicated for the group.
Descrizione

Tick the boxes corresponding to any of the inclusion criteria the subject failed

Tipo di dati

boolean

EXCLUSION CRITERIA
Descrizione

EXCLUSION CRITERIA

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) since birth, or planned use during the study period.
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

A family history of congenital or hereditary immunodeficiency.
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

Major congenital defects or serious chronic illness.
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

History of any neurologic disorders or seizures.
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C).
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

Hepatitis B vaccination given at birth outside the study.
Descrizione

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

Tipo di dati

boolean

RANDOMISATION / TREATMENT ALLOCATION
Descrizione

RANDOMISATION / TREATMENT ALLOCATION

Record treatment number
Descrizione

Treatment number

Tipo di dati

integer

GROUP HBV AT BIRTH
Descrizione

GROUP HBV AT BIRTH

Subject Number
Descrizione

Subject Number

Tipo di dati

integer

Has the EngerixTM-B vaccine been administered at birth?
Descrizione

ENGERIXTM-B VACCINE; Only for subjects in the HBV+DTPw-HBV/Hib Kft group.

Tipo di dati

boolean

Ritorna all'inizio della pagina

Similar models

VISIT 1 (Day 0 Birth)

1 moduli
  1. StudyEvent: ODM
    1. VISIT 1 (Day 0 Birth)
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
ELIMINATION CRITERIA DURING THE STUDY
Subject Number
Item
Subject Number
text
Elimination Criteria Planned Concomitant Vaccination
Item
Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the combined DTPw-HepB vaccine or DTPw-HepB/Hib vaccine, with the exception of oral poliovirus vaccine (OPV).
boolean
Elimination Criteria Unplanned Concomitant Medication
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
boolean
Elimination Criteria Immunodepressants
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
Elimination Criteria Prior Hepatitis B Vaccine
Item
Hepatitis B vaccine received after the first 72 hours of life.
boolean
Elimination Criteria Prior BCG Vaccine
Item
Bacille Calmette-Guérin (BCG) vaccine given after the first 2 weeks of life.
boolean
Elimination Criteria Previous Vaccination
Item
Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae or hepatitis B (except if indicated in the group allocation).
boolean
Elimination Criteria History of Diphteria
Item
History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B or Hib diseases.
boolean
Elimination Criteria Immunodeficient condition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
boolean
Elimination Criteria Allergies
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
boolean
Elimination Criteria Immuniglobulins
Item
Administration of immunoglobulins and/ or any blood products during the study period.
boolean
Elimination Criteria Unplanned Concomitant Vaccination
Item
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period.
boolean
Elimination Criteria Immunosuppressants
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
Elimination Criteria Planned Concomitant Vaccination
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol during the period from 30 days before each dose of vaccine and ending 30 after the last dose of vaccine, with the exception of OPV.
boolean
Elimination Criteria Immunoglobulins
Item
Administration of immunoglobulins and/or any blood products during the study period.
boolean
Elimination Criteria History of Immunodeficiency
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing required at study entry).
boolean
Item Group
CONTRAINDICATIONS TO SUBSEQUENT VACCINATION
Anaphylactic reaction
Item
Anaphylactic reaction following the administration of vaccines.
boolean
hypersensitivity to vaccine
Item
Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines.
boolean
Encephalopathy
Item
Encephalopathy (not due to another identifiable cause).
boolean
Disease at vaccination time
Item
Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature < 37.5 °C or rectal temperature < 38 °C.)
boolean
Temperature
Item
Axillary or oral temperature >= 37.5 °C or Rectal temperature >= 38 °C at the time of vaccination.
boolean
Item Group
PRECAUTIONS
Fever
Item
Fever = 40.0 °C (preferable axillary temperature or oral temperature) within 48 hours of vaccination, not due to another identifiable cause.
boolean
Collapse or Shock
Item
Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
boolean
Crying
Item
Persistent crying lasting >= 3 hours, occurring within 48 hours of vaccination.
boolean
Febrile Convulsions
Item
Convulsions with or without fever, occurring within 3 days of vaccination. There may be circumstances, such as a high incidence of pertussis, when the potential benefits outweigh possible risks.
boolean
Item
Reminder
text
Reminder
Code List
Reminder
CL Item
As with all injectable vaccines, appropriate medical treatment should always be readily available in case of (1)
CL Item
anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should (anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should)
CL Item
remain under medical supervision for 30 minutes after vaccination. (remain under medical supervision for 30 minutes after vaccination.)
CL Item
DTPw-HBV should be administered with caution to subjects with thrombocytopenia or a bleeding disorder (2)
CL Item
since bleeding may occur following an intramuscular administration to these subjects. (since bleeding may occur following an intramuscular administration to these subjects.)
CL Item
DTPw-HBV should under no circumstances be administered intravenously. (3)
Item Group
INFORMED CONSENT
Informed Consent
Item
I certify that Informed Consent has been obtained prior to any study procedure.
boolean
Informed Consent Date
Item
Informed Consent Date:
date
Item Group
DEMOGRAPHICS
Center number
Item
Center number:
integer
Date of birth
Item
Date of birth:
date
Item
Gender:
text
Gender
Code List
Gender:
CL Item
Male (1)
CL Item
Female (2)
Item
Race:
text
Race
Code List
Race:
CL Item
Black (1)
CL Item
Arabic/North African (2)
CL Item
White/Caucasian (3)
CL Item
East & South East Asian (4)
CL Item
South Asian (5)
CL Item
American Hispanic (6)
CL Item
Japanese (7)
CL Item
Other (8)
Item Group
ELIGIBILITY CHECK
Eligibility Check
Item
Did the subject meet all the entry criteria?
boolean
Item Group
INCLUSION CRITERIA
Reliability of Subjects
Item
Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
boolean
Subject's Mother seronegative for HBsAg
Item
Born to a mother known to be seronegative for HBsAg (documented laboratory result of HBsAg assay from a maternal blood sample is available).
boolean
Written Consent Obtained
Item
Written informed consent obtained from the parent or guardian of the subject.
boolean
Free of obvious health problems
Item
Free of obvious health problems as established by medical history and clinical examination before entering into the study.
boolean
Born after a normal gestation period
Item
Born after a normal gestation period (between 36 and 42 weeks).
boolean
A male or female less than or equal to 3 days (72 hours) of age at the time of the birth dose of Hepatitis B vaccination, if indicated for the group.
Item
A male or female less than or equal to 3 days (72 hours) of age at the time of the birth dose of Hepatitis B vaccination, if indicated for the group.
boolean
Item Group
EXCLUSION CRITERIA
Concomitant Medication
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) since birth, or planned use during the study period.
boolean
Immunodificient Condition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
boolean
Family History of Hereditary Immunodeficiency
Item
A family history of congenital or hereditary immunodeficiency.
boolean
Major congenital defects
Item
Major congenital defects or serious chronic illness.
boolean
History of neurologic disorders/seizures
Item
History of any neurologic disorders or seizures.
boolean
Administration of immunoglobulins
Item
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
boolean
Acute disease at the time of enrolment
Item
Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C).
boolean
Other conditions
Item
Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.
boolean
Hepatitis B vaccination given at birth outside the study.
Item
Hepatitis B vaccination given at birth outside the study.
boolean
Item Group
RANDOMISATION / TREATMENT ALLOCATION
Treatment number
Item
Record treatment number
integer
Item Group
GROUP HBV AT BIRTH
Subject Number
Item
Subject Number
integer
Vaccine Administration
Item
Has the EngerixTM-B vaccine been administered at birth?
boolean
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial